Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer.

Vadakekolathu J, Al-Juboori SIK, Johnson C, Schneider A, Buczek ME, Di Biase A, Pockley AG, Ball GR, Powe DG, Regad T.

Cell Death Dis. 2018 Mar 1;9(3):344. doi: 10.1038/s41419-018-0364-9.

2.

Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.

Cardwell CR, Pottegård A, Vaes E, Garmo H, Murray LJ, Brown C, Vissers PA, O'Rorke M, Visvanathan K, Cronin-Fenton D, De Schutter H, Lambe M, Powe DG, van Herk-Sukel MP, Gavin A, Friis S, Sharp L, Bennett K.

Breast Cancer Res. 2016 Dec 1;18(1):119.

3.

Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series.

Green AR, Soria D, Stephen J, Powe DG, Nolan CC, Kunkler I, Thomas J, Kerr GR, Jack W, Cameron D, Piper T, Ball GR, Garibaldi JM, Rakha EA, Bartlett JM, Ellis IO.

J Pathol Clin Res. 2016 Jan 15;2(1):32-40. doi: 10.1002/cjp2.32. eCollection 2016 Jan.

4.

Erratum to: Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.

Green AR, Soria D, Powe DG, Nolan CC, Aleskandarany M, Szász MA, Tőkés AM, Ball GR, Garibaldi JM, Rakha EA, Kulka J, Ellis IO.

Breast Cancer Res Treat. 2016 Aug;159(1):199. No abstract available.

5.

KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer-a targeted molecular approach.

Green WJ, Ball G, Hulman G, Johnson C, Van Schalwyk G, Ratan HL, Soria D, Garibaldi JM, Parkinson R, Hulman J, Rees R, Powe DG.

Br J Cancer. 2016 Jul 12;115(2):236-42. doi: 10.1038/bjc.2016.169. Epub 2016 Jun 23.

6.

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.

Green AR, Soria D, Powe DG, Nolan CC, Aleskandarany M, Szász MA, Tőkés AM, Ball GR, Garibaldi JM, Rakha EA, Kulka J, Ellis IO.

Breast Cancer Res Treat. 2016 May;157(1):65-75. doi: 10.1007/s10549-016-3804-1. Epub 2016 Apr 26. Erratum in: Breast Cancer Res Treat. 2016 Aug;159(1):199.

7.

Cytoplasmic PML promotes TGF-β-associated epithelial-mesenchymal transition and invasion in prostate cancer.

Buczek ME, Miles AK, Green W, Johnson C, Boocock DJ, Pockley AG, Rees RC, Hulman G, van Schalkwyk G, Parkinson R, Hulman J, Powe DG, Regad T.

Oncogene. 2016 Jun 30;35(26):3465-75. doi: 10.1038/onc.2015.409. Epub 2015 Nov 9.

8.

Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation.

Groot Kormelink T, Powe DG, Kuijpers SA, Abudukelimu A, Fens MH, Pieters EH, Kassing van der Ven WW, Habashy HO, Ellis IO, Blokhuis BR, Thio M, Hennink WE, Storm G, Redegeld FA, Schiffelers RM.

Oncotarget. 2014 May 30;5(10):3159-67.

9.

Beta-blocker usage and prostate cancer survival: a nested case-control study in the UK Clinical Practice Research Datalink cohort.

Cardwell CR, Coleman HG, Murray LJ, O'Sullivan JM, Powe DG.

Cancer Epidemiol. 2014 Jun;38(3):279-85. doi: 10.1016/j.canep.2014.03.011. Epub 2014 Apr 29.

PMID:
24786858
10.
11.

Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer.

Rakha EA, Soria D, Green AR, Lemetre C, Powe DG, Nolan CC, Garibaldi JM, Ball G, Ellis IO.

Br J Cancer. 2014 Apr 2;110(7):1688-97. doi: 10.1038/bjc.2014.120. Epub 2014 Mar 11.

12.

Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study.

McCourt C, Coleman HG, Murray LJ, Cantwell MM, Dolan O, Powe DG, Cardwell CR.

Br J Dermatol. 2014 Apr;170(4):930-8. doi: 10.1111/bjd.12894.

PMID:
24593055
13.

Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort.

Cardwell CR, Coleman HG, Murray LJ, Entschladen F, Powe DG.

Int J Epidemiol. 2013 Dec;42(6):1852-61. doi: 10.1093/ije/dyt196.

PMID:
24536096
14.

DACH1: its role as a classifier of long term good prognosis in luminal breast cancer.

Powe DG, Dhondalay GK, Lemetre C, Allen T, Habashy HO, Ellis IO, Rees R, Ball GR.

PLoS One. 2014 Jan 2;9(1):e84428. doi: 10.1371/journal.pone.0084428. eCollection 2014.

15.

Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink.

Cardwell CR, Flahavan EM, Hughes CM, Coleman HG, O'Sullivan JM, Powe DG, Murray LJ.

Cancer Causes Control. 2014 Jan;25(1):33-43. doi: 10.1007/s10552-013-0306-x. Epub 2013 Dec 6.

PMID:
24310109
16.

Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort.

Cardwell CR, Kunzmann AT, Cantwell MM, Hughes C, Baron JA, Powe DG, Murray LJ.

Gastroenterology. 2014 Mar;146(3):700-708.e2. doi: 10.1053/j.gastro.2013.11.005. Epub 2013 Nov 15.

PMID:
24239563
17.

Optimised laser microdissection of the human ocular surface epithelial regions for microarray studies.

Kulkarni BB, Powe DG, Hopkinson A, Dua HS.

BMC Ophthalmol. 2013 Oct 26;13:62. doi: 10.1186/1471-2415-13-62.

18.

β-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort.

Hicks BM, Murray LJ, Powe DG, Hughes CM, Cardwell CR.

Ann Oncol. 2013 Dec;24(12):3100-6. doi: 10.1093/annonc/mdt381. Epub 2013 Sep 19.

PMID:
24050955
19.

Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers.

Green AR, Powe DG, Rakha EA, Soria D, Lemetre C, Nolan CC, Barros FF, Macmillan RD, Garibaldi JM, Ball GR, Ellis IO.

Br J Cancer. 2013 Oct 1;109(7):1886-94. doi: 10.1038/bjc.2013.528. Epub 2013 Sep 5.

20.

The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer.

Habashy HO, Rakha EA, Ellis IO, Powe DG.

Breast Cancer Res Treat. 2013 Jul;140(2):307-16. doi: 10.1007/s10549-013-2614-y. Epub 2013 Jul 26.

PMID:
23887673
21.

A quantifier-based fuzzy classification system for breast cancer patients.

Soria D, Garibaldi JM, Green AR, Powe DG, Nolan CC, Lemetre C, Ball GR, Ellis IO.

Artif Intell Med. 2013 Jul;58(3):175-84. doi: 10.1016/j.artmed.2013.04.006. Epub 2013 Jun 18.

PMID:
23791088
22.

Norepinephrine inhibits the migratory activity of pancreatic cancer cells.

Stock AM, Powe DG, Hahn SA, Troost G, Niggemann B, Zänker KS, Entschladen F.

Exp Cell Res. 2013 Jul 15;319(12):1744-58. doi: 10.1016/j.yexcr.2013.04.015. Epub 2013 Apr 29.

PMID:
23639786
23.

Biomarker identification in breast cancer: Beta-adrenergic receptor signaling and pathways to therapeutic response.

Kafetzopoulou LE, Boocock DJ, Dhondalay GK, Powe DG, Ball GR.

Comput Struct Biotechnol J. 2013 May 21;6:e201303003. doi: 10.5936/csbj.201303003. eCollection 2013.

24.

Identification of novel breast cancer-associated transcripts by UniGene database mining and gene expression analysis in normal and malignant cells.

Laversin SA, Phatak VM, Powe DG, Li G, Miles AK, Hughes DC, Ball GR, Ellis IO, Gritzapis AD, Missitzis I, McArdle SE, Rees RC.

Genes Chromosomes Cancer. 2013 Mar;52(3):316-29. doi: 10.1002/gcc.22031. Epub 2012 Dec 8.

PMID:
23225347
25.

Local allergic rhinitis: concept, pathophysiology, and management.

Rondón C, Campo P, Togias A, Fokkens WJ, Durham SR, Powe DG, Mullol J, Blanca M.

J Allergy Clin Immunol. 2012 Jun;129(6):1460-7. doi: 10.1016/j.jaci.2012.02.032. Epub 2012 Apr 18. Review.

PMID:
22516477
26.

Idiopathic rhinitis.

Burns P, Powe DG, Jones NS.

Curr Opin Otolaryngol Head Neck Surg. 2012 Feb;20(1):1-8. doi: 10.1097/MOO.0b013e32834e8ef7. Review.

PMID:
22157164
27.

Norepinephrine promotes the β1-integrin-mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GROα release.

Strell C, Niggemann B, Voss MJ, Powe DG, Zänker KS, Entschladen F.

Mol Cancer Res. 2012 Feb;10(2):197-207. doi: 10.1158/1541-7786.MCR-11-0130. Epub 2011 Nov 29.

28.

EpCAM expression is an indicator of recurrence in basal-like breast cancer.

Agboola AJ, Paish EC, Rakha EA, Powe DG, Macmillan RD, Ellis IO, Green AR.

Breast Cancer Res Treat. 2012 Jun;133(2):575-82. doi: 10.1007/s10549-011-1813-7. Epub 2011 Oct 15.

PMID:
22002520
29.

A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer.

Habashy HO, Powe DG, Abdel-Fatah TM, Gee JM, Nicholson RI, Green AR, Rakha EA, Ellis IO.

Histopathology. 2012 May;60(6):854-63. doi: 10.1111/j.1365-2559.2011.03912.x. Epub 2011 Sep 10. Review.

PMID:
21906125
30.

Targeted therapies: Using β-blockers to inhibit breast cancer progression.

Powe DG, Entschladen F.

Nat Rev Clin Oncol. 2011 Aug 2;8(9):511-2. doi: 10.1038/nrclinonc.2011.123.

PMID:
21808268
31.

Detection and quantification of microRNAs in laser-microdissected formalin-fixed paraffin-embedded breast cancer tissues.

Khoshnaw SM, Powe DG, Ellis IO, Green AR.

Methods Mol Biol. 2011;755:119-42. doi: 10.1007/978-1-61779-163-5_10.

PMID:
21761299
32.

Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism.

Voss MJ, Möller MF, Powe DG, Niggemann B, Zänker KS, Entschladen F.

BMC Cancer. 2011 May 2;11:158. doi: 10.1186/1471-2407-11-158.

33.

Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR.

J Clin Oncol. 2011 May 20;29(15):1949-55. doi: 10.1200/JCO.2010.30.5037. Epub 2011 Apr 11.

PMID:
21483002
34.

Heterotrimeric G protein signaling in cancer cells with regard to metastasis formation.

Entschladen F, Zänker KS, Powe DG.

Cell Cycle. 2011 Apr 1;10(7):1086-91. Epub 2011 Apr 1. Review.

PMID:
21430442
35.

FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer.

Habashy HO, Rakha EA, Aleskandarany M, Ahmed MA, Green AR, Ellis IO, Powe DG.

Breast Cancer Res Treat. 2011 Aug;129(1):11-21. doi: 10.1007/s10549-010-1161-z. Epub 2011 Feb 19.

PMID:
21336599
36.

Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival.

Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, Entschladen F.

Oncotarget. 2010 Nov;1(7):628-38.

37.

Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.

Powe DG, Voss MJ, Habashy HO, Zänker KS, Green AR, Ellis IO, Entschladen F.

Breast Cancer Res Treat. 2011 Nov;130(2):457-63. doi: 10.1007/s10549-011-1371-z. Epub 2011 Feb 6.

PMID:
21298476
38.

Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer.

Abdel-Fatah TM, Powe DG, Ball G, Lopez-Garcia MA, Habashy HO, Green AR, Reis-Filho JS, Ellis IO.

J Pathol. 2010 Dec;222(4):388-99. doi: 10.1002/path.2775.

PMID:
20922713
39.

Comparative transcriptional profiling of the limbal epithelial crypt demonstrates its putative stem cell niche characteristics.

Kulkarni BB, Tighe PJ, Mohammed I, Yeung AM, Powe DG, Hopkinson A, Shanmuganathan VA, Dua HS.

BMC Genomics. 2010 Sep 29;11:526. doi: 10.1186/1471-2164-11-526.

40.

Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast.

Rakha EA, Patel A, Powe DG, Benhasouna A, Green AR, Lambros MB, Reis-Filho JS, Ellis IO.

Am J Surg Pathol. 2010 Oct;34(10):1472-9. doi: 10.1097/PAS.0b013e3181f01916.

PMID:
20871222
41.

Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation.

Kwok TC, Rakha EA, Lee AH, Grainge M, Green AR, Ellis IO, Powe DG.

Histopathology. 2010 Aug;57(2):212-9. doi: 10.1111/j.1365-2559.2010.03620.x.

42.

RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.

Habashy HO, Powe DG, Glaab E, Ball G, Spiteri I, Krasnogor N, Garibaldi JM, Rakha EA, Green AR, Caldas C, Ellis IO.

Breast Cancer Res Treat. 2011 Jul;128(2):315-26. doi: 10.1007/s10549-010-1073-y. Epub 2010 Aug 10.

PMID:
20697807
43.

'Entopy': local allergy paradigm.

Powe DG, Bonnin AJ, Jones NS.

Clin Exp Allergy. 2010 Jul;40(7):987-97. doi: 10.1111/j.1365-2222.2010.03536.x. Review.

PMID:
20642577
44.

MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups.

Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR.

Breast Cancer Res Treat. 2011 Jun;127(3):591-9. doi: 10.1007/s10549-010-1028-3. Epub 2010 Jul 11.

PMID:
20623333
45.

Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.

Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Ellis IO, Green AR.

Breast Cancer Res Treat. 2011 Jun;127(2):407-16. doi: 10.1007/s10549-010-1012-y. Epub 2010 Jul 9.

PMID:
20617378
46.

An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer.

Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, Ellis IO, Green AR.

Breast Cancer Res Treat. 2011 May;127(1):99-108. doi: 10.1007/s10549-010-0987-8. Epub 2010 Jun 17.

PMID:
20556505
47.

Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments.

Barros FF, Powe DG, Ellis IO, Green AR.

Histopathology. 2010 Apr;56(5):560-72. doi: 10.1111/j.1365-2559.2010.03494.x. Review. Erratum in: Histopathology. 2010 Jun;56(7):986.

PMID:
20459566
48.

CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis.

Albasri A, Aleskandarany M, Benhasouna A, Powe DG, Ellis IO, Ilyas M, Green AR.

Breast Cancer Res Treat. 2011 Feb;126(1):47-54. doi: 10.1007/s10549-010-0890-3.

PMID:
20390342
49.

The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.

Abdel-Fatah TM, Powe DG, Agboola J, Adamowicz-Brice M, Blamey RW, Lopez-Garcia MA, Green AR, Reis-Filho JS, Ellis IO.

J Pathol. 2010 Mar;220(4):419-34. doi: 10.1002/path.2663.

PMID:
20044801
50.

Hypoxia-induced EMAP-II transcription in colorectal cancer.

Youssef MM, Heng YM, Powe DG, Edgson J, Ellis IO, Murray C.

Egypt J Immunol. 2010;17(2):121-9.

PMID:
23082492

Supplemental Content

Support Center